MAPKeeper 301

  • Research type

    Research Study

  • Full title

    A Phase 3 Randomized, Open-Label Study of Atebimetinib in Combination with the Modified Gemcitabine and nab-Paclitaxel Regimen Versus the Standard Gemcitabine and nab-Paclitaxel Regimen for the Treatment of Patients with Metastatic Pancreatic Ductal Adenocarcinoma Cancer (MAPKeeper 301)

  • IRAS ID

    1014039

  • Contact name

    Adam Shiell

  • Contact email

    ashiell@immuneering.com

  • Sponsor organisation

    Immuneering Corporation

  • Clinicaltrials.gov Identifier

    NCT07562152

  • Research summary

    This study will test Atebimetinib to see if it can treat metastatic (i.e., spreading to other parts of the body) adenocarcinoma (i.e., cancer that begins in gland cells) affecting the small tubes (ducts) of the pancreas (i.e., metastatic pancreatic ductal adenocarcinoma [PDAC]). This type of cancer accounts for more than 90% of all pancreatic tumors and is very difficult to treat. This study will try to find out:
    • If Atebimetinib works, i.e., if Atebimetinib, used in combination with the chemotherapy regimen of gemcitabine plus nab-paclitaxel (i.e., one of the usual treatment options for patients with metastatic PDAC), may help people who have never been treated for this condition to live longer.
    • How safe Atebimetinib is, i.e., what side effects Atebimetinib causes and how bad they are.
    • How specific substances in the blood respond to Atebimetinib, i.e., how these substances (biomarkers) are linked to how well Atebimetinib works or why Atebimetinib may stop working.
    This study will assess if the combination of Atebimetinib and the chemotherapy regimen of gemcitabine plus nab-paclitaxel is more efficient compared to gemcitabine plus nab-paclitaxel (control group).
    The study will include about 510 participants, aged ≥18 years, diagnosed with metastatic PDAC within 12 weeks prior to enrollment, who are in good physical condition and have at least 1 detectable metastatic spot.
    The study contains 3 periods: Screening (can be up to 28 days before the start of treatment), Treatment (participants will regularly come back to the study site to receive IV infusion treatment (gemcitabine plus nab-paclitaxel), and for safety check-ups, blood draws, and other tests), and Follow-up (participants will come back to the study site about 30 days after they finish the study treatment for a safety check).
    Participation duration is about 12 months but may be shorter or longer depending upon how the cancer responds to the study treatment.

  • REC name

    West Midlands - Edgbaston Research Ethics Committee

  • REC reference

    26/WM/0126

  • Date of REC Opinion

    7 Aug 2026

  • REC opinion

    Further Information Favourable Opinion